TRxADE HEALTH (MEDS) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TRxADE HEALTH in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MEDS shares.
View MEDS analyst ratings or view top-rated stocks.

1 brokers have issued twelve-month price objectives for TRxADE HEALTH's stock. Their MEDS share price forecasts range from $26.25 to $26.25. On average, they expect the company's stock price to reach $26.25 in the next twelve months. This suggests a possible upside of 296.5% from the stock's current price.
View analysts price targets for MEDS or view top-rated stocks among Wall Street analysts.

TRxADE HEALTH's stock was trading at $6.0390 at the beginning of 2023. Since then, MEDS stock has increased by 9.6% and is now trading at $6.62.
View the best growth stocks for 2023 here.

TRxADE HEALTH saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 14,000 shares, an increase of 125.8% from the August 31st total of 6,200 shares. Based on an average trading volume of 740,200 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.6% of the company's stock are sold short.
View TRxADE HEALTH's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our MEDS earnings forecast.

TRxADE HEALTH, Inc. (NASDAQ:MEDS) announced its earnings results on Friday, August, 18th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.02. The business had revenue of $2.25 million for the quarter, compared to analyst estimates of $2.06 million. TRxADE HEALTH had a negative trailing twelve-month return on equity of 860.38% and a negative net margin of 43.29%.

Shares of TRxADE HEALTH reverse split on Thursday, June 22nd 2023. The 1-15 reverse split was announced on Thursday, June 22nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other TRxADE HEALTH investors own include Advanced Micro Devices (AMD), Biocept (BIOC), iBio (IBIO), Ollie's Bargain Outlet (OLLI), OPKO Health (OPK), Alto Ingredients (PEIX), Tiziana Life Sciences (TLSA) and Trevena (TRVN).

TRxADE HEALTH trades on the NASDAQ under the ticker symbol "MEDS."

TRxADE HEALTH's stock is owned by a number of institutional and retail investors. Top institutional investors include Barclays PLC (0.71%), Barclays PLC (0.71%) and Tower Research Capital LLC TRC (0.31%). Insiders that own company stock include Donald G Fell, Michael L Peterson, Prashant Patel and Surendra K Ajjarapu.
View institutional ownership trends.

Shares of MEDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MEDS stock can currently be purchased for approximately $6.62.

TRxADE HEALTH (NASDAQ:MEDS) has a market capitalization of $4.50 million and generates $11.45 million in revenue each year. The company earns $-3,470,000.00 in net income (profit) each year or ($6.3484) on an earnings per share basis.

TRxADE HEALTH's mailing address is 3840 Land O' Lakes Blvd., Land O' Lakes FL, 34639. The official website for the company is www.trxade.com. The company can be reached via phone at (800) 261-0281, via email at ir@trxade.com, or via fax at 800-265-6932.